94 results about "F protein" patented technology

The invention provides a bovine parainfluenza virus type 3 QL3 strain, and the preservation number of the bovine parainfluenza virus type 3 QL3 strain is CGMCC No.46469. The invention also provides a bovine parainfluenza inactivated vaccine containing the bovine parainfluenza virus type 3 QL3 strain and purified F protein and HN protein of the QL3 strain. The novel bovine parainfluenza virus type 3 inactivated vaccine is obtained by optimizing the antigen components of the bovine parainfluenza virus type 3 inactivated vaccine, and high-level neutralizing antibodies can be generated after immunizing cattle; the safety of the vaccine is improved through process optimization. Safety and potency test results show that after the inactivated vaccine is used for immunizing cattle, no adverse reaction exists, and high-level neutralizing antibodies are generated. Results show that the immune effect of the bovine parainfluenza virus type 3 inactivated vaccine can be improved.

The invention relates to a monoclonal antibody targeting RSV F protein, and a related product and application thereof. The monoclonal antibody (AD5) or the antigen binding fragment of the monoclonal antibody is specifically bound with the Site III antigen epitope of the RSV F protein. The antibody AD5 disclosed by the invention has the characteristics of targeting high-conservative epitope (Site III) and having high neutralizing activity, and overcomes the main defect that the neutralizing activity is not high when the existing listed antibody targets the high-conservative epitope.

The invention discloses a nano antibody of pre-F protein of a targeted respiratory syncytial virus and application of the nano antibody. The nano antibody comprises a heavy chain variable region, and the heavy chain variable region comprises heavy chain complementary determining regions CDR1, CDR2 and CDR3. The nano antibody disclosed by the invention can be specifically combined with RSV, and has a good application prospect in the aspect of RSV infection related diseases.

The invention relates to the technical field of vaccines, and particularly discloses a recombinant extracellular domain mutant trimer of a respiratory syncytial virus pre-fusion F protein, application of the recombinant extracellular domain mutant trimer and a vaccine. The mutant trimer comprises three recombinant F2-F1 extracellular domain protomers, and the recombinant F2-F1 extracellular domain protomers comprise three recombinant F2-F1 extracellular domain In some embodiments, the recombinant F2-F1 extracellular domain protomers each comprise a deletion of positions 104-144 and a peptide linker between positions 103 and 145, and comprise a L373R substitution and an engineered disulfide bond consisting of 55C and 188C, 149C and 458C substitutions, relative to a reference sequence. The recombinant extracellular domain mutant trimer of the F protein before fusion of the respiratory syncytial virus, provided by the invention, has higher yield, and the immunogenicity and stability of the antigen are further improved.

The invention discloses a Nipah virus F protein monoclonal antibody and application thereof, the antibody comprises an antibody 2D12 and an antibody 3B10, and the Nipah virus F protein monoclonal antibody is prepared from Nipah virus F protein immunogen. The specific anti-Nipah virus F protein monoclonal antibody pair is prepared and detected, the monoclonal antibody pair can be specifically combined with the Nipah virus F protein, is high in titer and good in affinity and has neutralizing activity, and meanwhile, the detection kit prepared on the basis of the antibody pair can effectively carry out Nipah virus detection; and technical support can be provided for treatment, epidemiological monitoring and diagnosis of Nipah virus infection.

The present invention relates to the field of immunology and molecular virology, and in particular relates to the field of the prevention and treatment of RSV. Specifically, provided are a monoclonal antibody capable of specifically binding to a new epitope between an Ø epitope and a V epitope on a pre-F protein or a new epitope between an II epitope and a V epitope, and the use thereof in the detection, prevention and / or treatment of RSV infection and / or diseases caused by the infections.

The application belongs to the technical field of biological medicine, and particularly relates to a RSV pre-fusion F protein mutant and application thereof. The RSV pre-fusion F protein mutant has good stability, high expression and / or immunogenicity, and can be used for preparing a RSV antibody, preventing RSV infection, preventing and / or treating a disease caused by RSV infection, detecting the presence or content of the RSV antibody in a sample, diagnosing RSV infection, and diagnosing a disease caused by RSV infection.

The invention relates to aqueous and lyophilized immunogenic compositions comprising an RSV F protein trimer in the prefusion conformation. The invention further relates to methods for storing an aqueous immunogenic composition comprising an RSV F protein trimer in the prefusion conformation as well as to methods for lyophilizing such aqueous immunogenic compositions.

This invention relates to a human monoclonal neutralizing antibody targeting the metapneumovirus F protein and its applications. It comprises a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region includes complementary determinant regions HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO:1, SEQ ID NO:2, and SEQ ID NO:3, respectively; and / or, the light chain variable region includes complementary determinant regions LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO:4, AAS, and SEQ ID NO:5, respectively. The metapneumovirus monoclonal neutralizing antibody MV32 of this invention can specifically bind to the metapneumovirus F antigen (approximately 0.6 nM) and exhibits good broad-spectrum neutralizing activity against representative strains such as hMPV A1, hMPV B1, and hMPV A2b. It also possesses certain in vivo protective and preventative effects and can be used for the prevention and treatment of human metapneumovirus infection, showing great application potential.

Provided herein are vaccines against RSV. In some embodiments, the vaccine comprises an mRNA encoding a stabilized pre-fusion RSV F protein immunogen linked to a dioxotetrahydropteridine synthase based scaffold.

To provide a method for producing an RSV F protein trimer by a fed-batch cell culture method.SOLUTION: Provided is a method comprising a temperature transition. The temperature is shifted to a lower temperature between about 30.0°C and about 32.0°C, preferably about 31.0°C.SELECTED DRAWING: Figure 2

The application belongs to the technical field of protein purification, and particularly relates to a recombinant human metapneumovirus pre-fusion F protein purification method, which comprises the following steps: filtering fermentation broth by using a deep filter to obtain fermentation clarified liquid; capturing the recombinant hMPV F protein from the fermentation clarified liquid by using hydroxyapatite to obtain purified liquid 1; inactivating viruses in the purified liquid 1 by using a low-pH method to obtain inactivated liquid; performing anion exchange chromatography on the inactivated liquid to obtain purified liquid 2; performing composite weak anion chromatography on the purified liquid 2 to obtain purified liquid 3; performing UF / DF on the purified liquid 3 to obtain ultrafiltrate; and performing virus-removing nanofiltration and sterile filtration on the ultrafiltrate to obtain a recombinant hMPV F stock solution. The method is simple, reproducible, suitable for large-scale production, and can be effectively used for producing a recombinant human metapneumovirus pre-fusion F protein vaccine.

Provided are an RSV F protein mutant, and a preparation method therefor and a use thereof. Provided is a mutant protein, the mutant protein being in the form of a monomer or a trimer, wherein the trimer is formed by three monomeric mutant proteins; the monomeric mutant protein is a fusion protein comprising a first polypeptide element derived from an RSV F protein and a trimerization domain element; in the first polypeptide element, a Pep27 fragment of the RSV F protein is replaced with a linker sequence; and the monomeric and trimeric mutant proteins are both bound by an antibody that specifically recognizes RSV pre-F. The mutant protein can stably remain in a pre-fusion state, can induce the production of specific IgG antibodies and neutralizing antibodies, has excellent immunogenicity, and can be used for the development of RSV vaccines.

The present invention relates to vaccination against respiratory syncytial virus (RSV), in particular to the use of a vaccine formulation comprising an RSV F fusion protein (RSV F protein) antigen and an adjuvant in methods of prevention of RSV infection and disease in older adults.

A respiratory syncytial virus (RSV) vaccine is provided, the nucleic acid comprising a polynucleotide encoding a mutant of an RSV F protein, the mutant to comprising one or more of the following mutations relative to a wild-type RSV F protein: a disulfide bond mutation, a cavity filling mutation, and an electrostatic mutation.

The present invention relates to a vaccine composition comprising a recombinant Nipah virus protein. The vaccine composition according to the present invention not only exhibits excellent immunogenicity against both the G protein and the F protein of Nipah virus, but also exhibits immunogenicity against the G protein and the F protein of Hendra virus, and thus can be used as a universal vaccine against Henipavirus. In addition, the vaccine composition has the characteristic of inducing cell-mediated immune responses, and therefore can be provided as a formulation for enhancing specific immune responses to an administered drug such as an adjuvant or a vaccine.

The application discloses a bovine parainfluenza virus 3A and 3C type polyepitope antigen peptide, a complex thereof and application. The polyepitope antigen peptides BPMEV-3A and BPMEV-3C have amino acid sequences as shown in SEQ ID NO:1 and SEQ ID NO:3 respectively, and are connected by screening CTL epitopes, HTL epitopes and B cell epitopes from HN and F proteins of BPIV-3A and BPIV-3C strains. Animal immunization tests show that the antigen peptide and the complex thereof can effectively stimulate the body to produce specific IgG antibodies and neutralizing antibodies, induce Th1 type cellular immune response, and effectively eliminate viruses and reduce lung tissue lesions, and show good immunogenicity and protection effect. The application provides an efficient and safe vaccine candidate for prevention and control of BPIV-3, and has a good application prospect.

The present disclosure relates to nanobodies, therapeutic agents, compositions and methods for the diagnosis, prevention, amelioration and treatment of henipaviral infections. Herein disclosed are camelid-derived nanobodies that specifically bind the F protein of both Nipah virus (NiV) and Hendra virus (HeV). The disclose nanobodies effectively bind and potently neutralise both of these viruses, making these nanobodies suitable therapeutic agents for the prevention or treatment of henipaviral infections.

The present invention relates to a respiratory syncytial virus subtype A (RSV-A) recombinant F protein, a polynucleotide encoding the same, a nucleic acid construct comprising the polynucleotide, an expression vector comprising the nucleic acid construct, a host cell in which the polynucleotide, the nucleic acid construct or the expression vector is transformed or transfected, a stabilized trimer formed therefrom, and a method for preparing the same. An immunogenic composition comprising any of the foregoing, and its use in the preparation of a vaccine for the prevention and / or treatment of respiratory syncytial virus infection. The RSV-A recombinant F protein comprises at least one specific epitope of the pre-fusion F protein, can form a stable F protein trimer with a pre-fusion conformation, and is stable in expression, uniform in form and greatly improved in yield; the formed F protein trimer has good immunogenicity, can stimulate an organism to generate high-level antibody titer, and has great significance in clinical treatment and prevention and control of the respiratory syncytial virus.

An immunogenic composition comprising recombinant peptides and proteins comprising respiratory syncytial virus (RSV) viral antigens and immunogens, such as RSVF protein peptides. The immunogenic composition comprises a secreted fusion protein, the secreted fusion protein comprises a soluble RSV virus antigen, and the soluble RSV virus antigen and a collagen C-terminal part are linked through in-frame fusion to form a disulfide bond linked trimeric fusion protein. The immunogenic compositions may be used to generate an immune response, for example, in the treatment or prevention of RSV infection. The immunogenic compositions may be used in vaccine compositions, for example as part of prophylactic and / or therapeutic vaccines. Also provided are methods of producing the recombinant peptides and proteins, prophylactic, therapeutic and / or diagnostic methods, and related kits.

The application belongs to the technical field of biological medicine, and particularly relates to a RSV pre-fusion F protein mutant and application thereof. The RSV pre-fusion F protein mutant has good stability, high expression and / or immunogenicity, and can be used for preparing a RSV antibody, preventing RSV infection, preventing and / or treating a disease caused by RSV infection, detecting the presence or content of the RSV antibody in a sample, diagnosing RSV infection, and diagnosing a disease caused by RSV infection.

A vaccine against RSV is provided herein. The vaccine comprises an mRNA encoding a stabilized RSV prefusion F protein immunogen, linked to a lumazine synthase-based scaffold.

The invention relates to the technical field of molecular diagnosis of respiratory tract infection pathogens, in particular to a molecular marker combination for typing respiratory tract infection pathogens (human metapneumovirus, HMPV) and application of the molecular marker combination in preparation of a kit for typing wild and mutant strains of HMPV. The molecular marker combination is HMPV virus F protein K479R and N482S mutations, and the molecular marker combination is associated with HMPV strain metal ion antagonism. By detecting the marker, the correlation analysis of strain types and functional characteristics can be realized, and the double mutation sites have no obvious function change when acting independently, so that the typing specificity and functional correlation are further ensured. Specifically, the molecular marker combination is associated with the metal ion antagonism of the HMPV strain, and the antagonism of the HMPV to the metal ions is enhanced by double mutation.

The present application relates to a human monoclonal neutralizing antibody targeting metapneumovirus F protein and application thereof, which comprises a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises: a complementarity determining region HCDR1 having an amino acid sequence as shown in SEQ ID NO:1, a complementarity determining region HCDR2 as shown in SEQ ID NO:2, and a complementarity determining region HCDR3 as shown in SEQ ID NO:3; and / or the light chain variable region comprises: a complementarity determining region LCDR1 having an amino acid sequence as shown in SEQ ID NO:4, a complementarity determining region LCDR2 as shown in AAS, and a complementarity determining region LCDR3 as shown in SEQ ID NO:5. The metapneumovirus monoclonal neutralizing antibody MV61 of the present application can specifically bind to metapneumovirus F antigen, has high affinity (about 0.18nM), high neutralization activity to different mutant strains of metapneumovirus, and excellent broad spectrum.

This invention discloses a single-domain antibody that specifically binds to human metapneumovirus (HMV) and its applications. The single-domain antibody and its antigen-binding fragment provided by this invention can specifically recognize and bind to the pre-F protein of HMV, neutralizing the virus. It exhibits particularly high neutralizing activity against HMV strains A1, A2, and B1, effectively preventing and controlling HMV infection. This invention provides a new approach for the detection of HMV and the prevention and treatment of HMV-related diseases, and has broad application prospects.

The present disclosure relates to fusion proteins, and uses thereof, comprising a viral fusion protein ectodomain linked to one or more heptad repeats (HR) from the SARS-COV-2 spike (S) protein or the respiratory syncytial virus (RSV) F protein. The viral fusion proteins are suitable for use as vaccines.

The present disclosure relates to vaccine compositions against respiratory syncytial virus (RSV) that are tomato-based and their methods of production. The vaccine compositions comprise tomato fruit and plant-expressed fragment of RSV F protein, preferably the ectodomain of the RSV F protein. In some aspects, the vaccine compositions comprise tomato fruit and plant-expressed human immunodeficiency virus (HIV) virus-like particle (VLP) wherein the fragment of RSV F protein is displayed on the VLP surface. For example, the vaccine compositions are tomato paste spiked with the plant-expressed HIV VLP. In certain embodiments, the plant-expressed HIV VLP comprises a Gag protein; a fragment of gp41 protein, which comprises the C-terminal cytosolic domain of the gp41 protein; and a fragment of RSV F protein, wherein the fragment of RSV F protein lacks the p27 region and the C-terminus of the fragment of RSV F protein is linked to the N-terminus of the fragment of gp41 protein.

The present disclosure relates to compositions comprising a group B streptococcus (GBS) polysaccharide-protein conjugate and a respiratory syncytial virus (RSV) F protein and / or RNA polynucleotide encoding an antigen derived from RSV The present disclosure further relates to methods and uses of the compositions comprising a GBS polysaccharide-protein conjugate and RSV F protein and / or RNA polynucleotide encoding an antigen derived from RSV for the prevention of a disease or infection associated with GBS and / or RSV.

The invention provides polynucleotide for coding an RSV (Respiratory Syndrome Virus) pre-fusion F protein and application of the polynucleotide in an mRNA (Messenger Ribonucleic Acid) vaccine. The sequence of the polynucleotide is as shown in SEQ ID No: 1. Experiments prove that the antigen-specific IgG titer of the polynucleotide, the vaccine and the pharmaceutical composition provided by the invention is 2-4 times that of an unoptimized sequence, so that more efficient expression of target protein in vivo is prompted, and meanwhile, the geometric mean titer value of a neutralizing antibody is also higher than that of the unoptimized sequence, so that good immunogenicity is prompted. The GMT value and the antigen specificity IFN-gamma, IL-5 and IL-17A levels of the neutralizing antibody generated by induction of the RSV mRNA vaccine provided by the invention are obviously higher than those of a control group in the prior art, so that the RSV mRNA vaccine has excellent application prospects.

This invention relates to a monoclonal antibody against RSV virus and its application; the monoclonal antibody or its antigen-binding fragment comprises one or more of the following (1) to (2): (1) three heavy chain complementarity-determining regions in the heavy chain variable region as shown in SEQ ID NO:1, and three light chain complementarity-determining regions in the light chain variable region as shown in SEQ ID NO:2; or, (2) three heavy chain complementarity-determining regions in the heavy chain variable region as shown in SEQ ID NO:9, and three light chain complementarity-determining regions in the light chain variable region as shown in SEQ ID NO:10. The antibody or its antigen-binding fragment of this invention can specifically bind to RSV F protein, and has an affinity of 10 for the DS2 antigen. ‑9 M; can highly inhibit RSV live virus infection of target cells, IC 50 The concentration was 1.27 ng / mL, indicating broad application prospects in clinical practice.